ASIT Biotech

ASIT Biotech S.A. is a biopharmaceutical company based in Liège, Belgium, specializing in the research, development, and commercialization of immunotherapy products aimed at treating allergies. The company's lead product, gp-ASIT+, is currently undergoing Phase III trials for grass pollen rhinitis. Additionally, ASIT Biotech is developing hdm-ASIT+ for house dust mite asthma and pnt-ASIT+ for peanut allergy. Founded in 1997 and formerly known as BioTech Tools SA, the company has focused on utilizing its ASIT+ technology platform to create breakthrough immunotherapy solutions for allergy patients.